2022
DOI: 10.1101/2022.04.22.489147
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Chemogenetic disconnection between the orbitofrontal cortex and the rostromedial caudate nucleus disrupts motivational control of goal-directed action

Abstract: The orbitofrontal cortex (OFC) and its major downstream target within the basal ganglia—the rostromedial caudate nucleus (rmCD)—are involved in reward-value processing and goal-directed behavior. However, a causal contribution of the pathway linking these two structures to goal-directed behavior has not been established. Using the chemogenetic technology of Designer Receptors Exclusively Activated by Designer Drugs with a crossed inactivation design, we functionally and reversibly disrupted interactions betwee… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 64 publications
0
1
0
Order By: Relevance
“…Chemogenetic tools using mutated muscarinic acetylcholine receptors, called Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), have been widely used in rodents and other small animals (Roth, 2016). DREADDs have also proven to be useful in nonhuman primates (NHPs), where they can manipulate neuronal activity in a specific cell type or neural pathway (Mimura et al, 2021;Oguchi et al, 2021;Perez et al, 2022) or simultaneously and discretely in multiple brain regions (Eldridge et al, 2016;Nagai et al, 2016Nagai et al, , 2020Raper et al, 2019;Hayashi et al, 2020;Hori et al, 2021;Oyama et al, 2021Oyama et al, , 2022Roseboom et al, 2021). As such, they provide an opportunity for identifying the regions and pathways that are causally responsible for cognitive/emotional functions.…”
Section: Introductionmentioning
confidence: 99%
“…Chemogenetic tools using mutated muscarinic acetylcholine receptors, called Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), have been widely used in rodents and other small animals (Roth, 2016). DREADDs have also proven to be useful in nonhuman primates (NHPs), where they can manipulate neuronal activity in a specific cell type or neural pathway (Mimura et al, 2021;Oguchi et al, 2021;Perez et al, 2022) or simultaneously and discretely in multiple brain regions (Eldridge et al, 2016;Nagai et al, 2016Nagai et al, , 2020Raper et al, 2019;Hayashi et al, 2020;Hori et al, 2021;Oyama et al, 2021Oyama et al, , 2022Roseboom et al, 2021). As such, they provide an opportunity for identifying the regions and pathways that are causally responsible for cognitive/emotional functions.…”
Section: Introductionmentioning
confidence: 99%